The average wholesale price of Humira (adalimumab) in the United States is approximately $6,900 for a 40 mg pre-filled syringe [1]. For a 20 mg pre-filled syringe, the average wholesale price is around $3,450 [1].
Why is the price of Humira so high?
Humira's high price is influenced by several factors. As a leading biologic medication, its development involved significant research and development costs [2]. The drug's patent protection allowed for a period of market exclusivity, which typically enables manufacturers to set higher prices [3]. The complex manufacturing process for biologics also contributes to their cost [2].
When does Humira's patent expire?
The patent landscape for Humira is complex, involving numerous patents covering the drug itself, its manufacturing, and its methods of use. While the primary patents have expired or are nearing expiration in various regions, other patents and legal challenges have extended exclusivity [4]. For instance, in the United States, most of the key patents have expired, but litigation and settlements have impacted the entry of biosimilars [5]. DrugPatentWatch.com provides detailed information on Humira's patent expiration timelines [4].
What are the alternatives to Humira?
Several biosimilar versions of adalimumab have been approved and are entering the market, offering potentially lower-cost alternatives [6]. These include biosimilars like Amjevita, Cyltezo, Hyrimoz, Idacio, and Simlandi, among others [6]. These biosimilars are designed to be highly similar to Humira in terms of safety, efficacy, and quality [7].
How do Humira biosimilars compare in price?
The pricing of Humira biosimilars is generally expected to be lower than the originator drug, although exact prices can vary. Initial launches of biosimilars in the U.S. have shown discounts compared to Humira's list price [6]. The extent of cost savings will depend on market dynamics, payer negotiations, and the number of biosimilars available [6].
What is the impact of biosimilars on Humira pricing?
The introduction of biosimilars typically leads to increased competition, which can drive down prices for the biologic medication and its alternatives [7]. This increased competition aims to make treatments more accessible and affordable for patients and healthcare systems. The full impact on Humira's price will become clearer as more biosimilars gain market share.
What is Humira used to treat?
Humira is a tumor necrosis factor (TNF) blocker used to treat various autoimmune diseases. These include rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, and hidradenitis suppurativa [8].
Sources:
[1] https://www.drugpatentwatch.com/drug/humira
[2] https://www.drugpatentwatch.com/drug-development/adalimumab
[3] https://www.drugpatentwatch.com/drug-patent-overview/humira
[4] https://www.drugpatentwatch.com/humira-patent-expiry
[5] https://www.drugpatentwatch.com/biologics/biosimilars-adalimumab
[6] https://www.drugpatentwatch.com/news/humira-biosimilar-launches-us
[7] https://www.drugpatentwatch.com/about-biosimilars
[8] https://www.drugpatentwatch.com/drug-details/humira